ClinVar Miner

Submissions for variant NM_001352514.2(HLCS):c.1910C>T (p.Pro637Leu)

gnomAD frequency: 0.00005  dbSNP: rs536067980
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001247264 SCV001420674 uncertain significance Holocarboxylase synthetase deficiency 2022-08-16 criteria provided, single submitter clinical testing This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 490 of the HLCS protein (p.Pro490Leu). This variant is present in population databases (rs536067980, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with HLCS-related conditions. ClinVar contains an entry for this variant (Variation ID: 971476). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt HLCS protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV004987004 SCV005599752 uncertain significance Inborn genetic diseases 2024-11-07 criteria provided, single submitter clinical testing The c.1469C>T (p.P490L) alteration is located in exon 8 (coding exon 5) of the HLCS gene. This alteration results from a C to T substitution at nucleotide position 1469, causing the proline (P) at amino acid position 490 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Natera, Inc. RCV001247264 SCV002083731 uncertain significance Holocarboxylase synthetase deficiency 2020-02-26 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.